We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Stool for Fecal Transplants Company Earns FDA Warning Letter

Stool for Fecal Transplants Company Earns FDA Warning Letter

March 15, 2024

Human Microbes, a company promoting the value and sale of fecal microbiota transplants (FMT), has received an FDA Warning Letter listing a litany of regulatory violations, including lack of an FDA-approved BLA.

Showcasing a video labeled “We want your poop,” the website — humanmicrobes.org — touts the unauthenticated potential benefits of FMT capsules, enemas and infusions to treat a variety of conditions that include obesity, mental illness, multiple sclerosis, autism and diabetes.

As FMT is highlighted on the website as a “lifesaving treatment” and advertised as having “shown promising results in clinical trials,” the products in treatment are thus classified as “drugs” and “new drugs” under the Federal Food, Drug, and Cosmetic (FD&C) Act, the letter says. The Warning Letter confirms that the organization — to lawfully market a drug that is also a biological product — must have an FDA-approved BLA confirming the product is safe, pure and potent.

Read the FDA warning letter here.

To read the whole story, click here to subscribe.

Related Topics

Drugs Inspections and Audits

    Upcoming Events

    • 21Mar

      FDA as a Development Partner: A New Approach to Product Review Meetings

    • 28Mar

      The Inflation Reduction Act (IRA): How Will It Impact Drug Development?

    • 04Apr

      Managing Data and Documentation for FDA Inspections and Remote Assessments

    • 11Apr

      Integrating Regulatory Intelligence into Supplier Management

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    • 14May

      2024 Avoca Quality Consortium Summit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Asymptomatic People Should Be Included in Alzheimer’s Trials, Draft Guidance Says

    • Draft Guidance Addresses Device Cybersecurity for Product Lifecycle

    • Stool for Fecal Transplants Company Earns FDA Warning Letter

    • Dermatology Apps Inconsistent, Not FDA Approved, Says JAMA Study

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing